Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|January 25, 2017
It's a long way to the top (if you want to personalize immunotherapy)Sarah Haebe, Oliver WeigertHaematologica|August 10, 2012
TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11qAngela Garding, Nupur Bhattacharya, Sarah Haebe, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Intratumoral Immunotherapy for Early-stage Solid TumorsWan Xing Hong, Sarah Haebe, Andrew S Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2025
A Phase I Clinical Trial Adding OX40 Agonism to In Situ Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human StudiesTanaya Shree, Debra Czerwinski, Sarah Haebe, et al.Blood Advances|April 4, 2019
Impact of age on clinical risk scores in follicular lymphomaStefan Alig, Vindi Jurinovic, Alessandro Pastore, et al.Cancers|November 14, 2023
PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma-A Matched-Pair AnalysisSarah Haebe, Alessia Fraccaroli, Elena Stauffer, et al.International Journal of Cancer|May 16, 2014
Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6Nupur Bhattacharya, Michaela Reichenzeller, Maiwen Caudron-Herger, et al.Cancer Cytopathology|November 15, 2021
Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapyKelly L Mooney, Debra K Czerwinski, Tanaya Shree, et al.NPJ Precision Oncology|January 25, 2025
Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patientsSarah Haebe, Gesa Schuebbe, Philipp Jurmeister, et al.Cancers|August 29, 2024
Treosulfan-Versus Melphalan-Based Reduced Intensity Conditioning in HLA-Haploidentical Transplantation for Patients ≥ 50 Years with Advanced MDS/AMLAlessia Fraccaroli, Elena Stauffer, Sarah Haebe, et al.Pageof 3